1.A case of Budd-Chiari syndrome with high antiphospholipid antibody in a patient with systemic lupus erythematosus.
Yeoun Yeon YUN ; Kyung Ah YOH ; Hyoung In YANG ; Sung Hwan PARK ; Sang Heon LEE ; Chul Soo CHO ; Ho Youn KIM
The Korean Journal of Internal Medicine 1996;11(1):82-86
Antiphospholipid syndrome is characterized by recurrent episodes of arterial and venous thrombosis, spontaneous fetal losses, thrombocytopenia and persistently elevated levels of antiphospholipid antibodies. We experienced a case of Budd-Chiari syndrome in a 32-year old female lupus patient who was presented with left leg edema, ascites and esophageal varix. The clinical and laboratory findings were compatible with the cirteria for systemic lupus erythematosus (SLE) and she was found to have anticardiolipin antibody, thrombocytopenia and prolonged partial thromboplastin time. Initially, she was treated with intravenous heparin and uroki nase and she was followed up with warfarin, baby aspirin and steroids.
Adult
;
Angiography
;
Animal
;
Antibodies, Antiphospholipid/blood*
;
Case Report
;
Drug Therapy, Combination
;
Female
;
Hepatic Vein Thrombosis/complications
;
Hepatic Vein Thrombosis/diagnosis*
;
Hepatic Vein Thrombosis/drug therapy
;
Human
;
Lupus Erythematosus, Systemic/complications
;
Lupus Erythematosus, Systemic/diagnosis*
;
Lupus Erythematosus, Systemic/drug therapy
;
Tomography, X-Ray Computed
2.Rhupus syndrome.
Jae Ki MIN ; Kyoung Ann LEE ; Hae Rim KIM ; Ho Youn KIM ; Sang Heon LEE
The Korean Journal of Internal Medicine 2015;30(1):131-131
No abstract available.
Antirheumatic Agents/therapeutic use
;
Arthritis, Rheumatoid/blood/*complications/diagnosis/drug therapy/physiopathology
;
Biological Markers/blood
;
Drug Therapy, Combination
;
Facial Dermatoses/complications/diagnosis
;
Female
;
Hand Joints/physiopathology/radiography
;
Humans
;
Immunosuppressive Agents/therapeutic use
;
Inflammation Mediators/blood
;
Knee Joint/physiopathology/radiography
;
Lupus Erythematosus, Systemic/blood/*complications/diagnosis/drug therapy
;
Middle Aged
;
Syndrome
;
Treatment Outcome
3.Factors related to outcomes in lupus-related protein-losing enteropathy.
Doo Ho LIM ; Yong Gil KIM ; Seung Hyeon BAE ; Soomin AHN ; Seokchan HONG ; Chang Keun LEE ; Bin YOO
The Korean Journal of Internal Medicine 2015;30(6):906-912
BACKGROUND/AIMS: Protein-losing enteropathy (PLE), characterized by severe hypoalbuminemia and peripheral edema, is a rare manifestation of systemic lupus erythematosus. This present study aimed to identify the distinctive features of lupus-related PLE and evaluate the factors related to the treatment response. METHODS: From March 1998 to March 2014, the clinical data of 14 patients with lupus PLE and seven patients with idiopathic PLE from a tertiary center were reviewed. PLE was defined as a demonstration of protein leakage from the gastrointestinal tract by either technetium 99m-labelled human albumin scanning or fecal alpha1-antitrypsin clearance. A positive steroid response was defined as a return of serum albumin to > or = 3.0 g/dL within 4 weeks after initial steroid monotherapy, and remission as maintenance of serum albumin > or = 3.0 g/dL for at least 3 months. A high serum total cholesterol level was defined as a level of > or = 240 mg/dL. RESULTS: The mean age of the lupus-related PLE patients was 37.0 years, and the mean follow-up duration was 55.8 months. Significantly higher erythrocyte sedimentation rate and serum total cholesterol levels were found for lupus PLE than for idiopathic PLE. Among the 14 patients with lupus PLE, eight experienced a positive steroid response, and the serum total cholesterol level was significantly higher in the positive steroid response group. A positive steroid response was associated with an initial high serum total cholesterol level and achievement of remission within 6 months. CONCLUSIONS: In lupus-related PLE, a high serum total cholesterol level could be a predictive factor for the initial steroid response, indicating a good response to steroid therapy alone.
Adult
;
Aged
;
Biomarkers/blood
;
Cholesterol/blood
;
Drug Therapy, Combination
;
Edema/diagnosis/drug therapy/*etiology
;
Female
;
Glucocorticoids/therapeutic use
;
Humans
;
Hypoalbuminemia/diagnosis/drug therapy/*etiology
;
Immunosuppressive Agents/therapeutic use
;
Lupus Erythematosus, Systemic/*complications/diagnosis/drug therapy
;
Male
;
Middle Aged
;
Protein-Losing Enteropathies/diagnosis/drug therapy/*etiology
;
Remission Induction
;
Risk Factors
;
Serum Albumin/metabolism
;
Tertiary Care Centers
;
Time Factors
;
Treatment Outcome
4.Clinical significance of antiphospholipid antibody in pediatric patients and review of literature.
Hui-Jie XIAO ; Ji-Yun YANG ; Tian-Ji GAO ; Jian-Ping HUANG ; Yong YAO ; Yan ZHANG
Chinese Journal of Pediatrics 2004;42(8):571-573
OBJECTIVEAntiphospholipid antibody (APL) is a particularly important laboratory diagnostic criterion for antiphospholipid syndrome (APS). The significances of positive APL in childhood are seldom reported nor fully understood. The purpose of this study was to analyze 13 cases with positive APL seen in our hospital and to study the relationship between the positive rates of APL and various clinical diseases especially systemic lupus erythematosus (SLE) in order to improve the clinical diagnoses and treatment level of APS in children.
METHODSThe clinical data collected from 2000 to 2002 of 13 hospitalized children with positive APL were retrospectively evaluated. Enzyme linked immunosorbent assay (ELISA) and indirect immunofluorescence technique were used respectively to detect APL and antineutrophil cytoplasmic autoantibodies (ANCA) of sera from those children. Other various indexes were also detected according to different characteristics of different diseases.
RESULTSEight cases had SLE; 2 had acute post-streptococcal infections. The other 3 cases did not show any evidences of primary diseases; they probably had primary APS. SLE was the most common primary diseases to cause development of APL and the cases with SLE showed more severe cutaneous vasculitis than SLE patients who were negative for APL. There was no significant relationship between the positive rates of APL and that of ANCA. Eight APL positive cases complicated with thrombocytopenia and bleeding were treated with high dosage of immunoglobulin [400 mg/(kg.d), for 3 - 5 d] intravenously; the clinical conditions of these cases were ameliorated soon. While the 5 cases who had thrombotic vasculitis and thromboembolism were treated with anticoagulant and antithrombotic therapy with low molecular weight heparin [50 - 100 U/(kg.d)], which led to good clinical effects.
CONCLUSIONSThe clinical manifestations of children positive for APL were somehow different from those of adults. Positive APL itself may be nonspecific, it can occur from different causes of diseases. APL detection may be useful to suggest anticoagulant and/or antithrombosis therapy. Treatments for APS should be variable according to different causes and severity of diseases, in the cases of thrombocytopenia and bleeding, high dose intravenous immunoglobulin should be given as soon as possible, while in the cases of thrombotic vasculitis and thromboembolism, anticoagulant and antithrombotic therapy should be given soon.
Adult ; Antibodies, Antineutrophil Cytoplasmic ; blood ; Antibodies, Antiphospholipid ; blood ; immunology ; Anticoagulants ; therapeutic use ; Antiphospholipid Syndrome ; blood ; complications ; diagnosis ; therapy ; Child ; Fibrinolytic Agents ; therapeutic use ; Hemorrhage ; etiology ; therapy ; Humans ; Immunoglobulins, Intravenous ; therapeutic use ; Lupus Erythematosus, Systemic ; immunology ; Streptococcal Infections ; immunology ; Thrombocytopenia ; etiology ; therapy ; Thromboembolism ; drug therapy ; etiology ; Thrombosis ; drug therapy ; etiology ; Vasculitis ; drug therapy ; etiology
5.Serial Interferon-gamma Release Assays for the Diagnosis of Latent Tuberculosis Infection in Patients Treated with Immunosuppressive Agents.
Kyeong Hee KIM ; Sung Won LEE ; Won Tae CHUNG ; Byoung Gwon KIM ; Kwang Sook WOO ; Jin Yeong HAN ; Jeong Man KIM
The Korean Journal of Laboratory Medicine 2011;31(4):271-278
BACKGROUND: We assessed the efficacy of serial interferon-gamma release assays (IGRAs) for the diagnosis of latent tuberculosis infection (LTBI) in patients receiving immunosuppressive agents for treatment of rheumatic diseases in Korea. METHODS: Of 276 patients who underwent consecutive screening with one of two IGRAs [QuantiFERON-TB Gold or QuantiFERON-TB Gold In-Tube], 66 patients were evaluated by the serial IGRA for detection of LTBI during therapy with immunosuppressive agents. Information on clinical diagnosis, medication, previous TB, blood cell count, tuberculin skin test, and interferon-gamma (IFN-gamma) level measured by IGRA was collected. RESULTS: Of the 66 patients, the initial IGRA was positive in 24.2%, negative in 65.2%, and indeterminate in 10.6%. Forty-six patients (69.7%) showed consistent IGRA results during follow-up, and 13 patients (19.7%) had consistently positive results. IGRA conversion rate was 12.1% (8/66) and reversion rate was 4.5% (3/66). Conversion of IGRA results was only observed in ankylosing spondylitis patients, and the median interval between the two tests in patients with conversion was 8.5 months. The mean IFN-gamma level in the group of patients with consistently positive IGRA results was higher than that in the group with inconsistently positive results, although this trend was not statistically significant (P=0.293). Indeterminate results were observed most frequently in patients with systemic lupus erythematosus. CONCLUSIONS: In patients receiving immunosuppressive agents, both IGRA conversions and reversions were observed. Serial IGRA testing may not be needed in patients with a positive initial IGRA result showing high IFN-gamma levels, because of high consistency in the test results.
Adult
;
Blood Cell Count
;
Female
;
Follow-Up Studies
;
Humans
;
Immunosuppressive Agents/*therapeutic use
;
Interferon-gamma/*analysis
;
*Interferon-gamma Release Tests
;
Latent Tuberculosis/complications/*diagnosis/metabolism
;
Lupus Erythematosus, Systemic/complications/diagnosis/metabolism
;
Male
;
Middle Aged
;
Rheumatic Diseases/complications/diagnosis/drug therapy
;
Spondylitis, Ankylosing/complications/diagnosis/metabolism
;
Tuberculin Test